ICMR task force meets to discuss inclusion of Pfizer’s Paxlovid for Covid treatment
The Indian Council of Medical Research’s (ICMR) National Task Force on Covid-19 is likely to meet this week to review data available on antiviral drug Paxlovid to decide on its inclusion in the treatment guidelines, people aware of the matter told ET.
Last week, India’s drug regulator had approved Pfizer’s Paxlovid for restricted emergency use against Covid-19 amid a rise in infections in the country. Hyderabad-based Hetero Labs will manufacture the generic version of the drug, touted as a game changer in the fight against the disease. “We are regularly looking into the new drugs and new therapies and will be reviewing Paxlovid soon,” said Samiran Panda, head of epidemiology and infectious diseases at ICMR.